Please login to the form below
lebrikizumab
This page shows the latest lebrikizumab news and features for those working in and with pharma, biotech and healthcare.
Almirall shares positive topline results from atopic dermatitis trials
These studies are part of the clinical development programme for lebrikizumab in AD, assessing over 2, 000 patients. ... Patients involved in the two trials who were treated with lebrikizumab for a year continued to have relief from itching.
Latest news
-
Lebrikizumab achieves skin clearance in pivotal phase 3 atopic dermatitis trials
a 75% reduction in disease severity at 16 weeks when receiving lebrikizumab monotherapy in the programme. ... The safety profile of the 16-week period was consistent with prior lebrikizumab studies in atopic dermatitis.
-
Lilly will aim for one $1bn-$5bn deal per quarter in 2020
The Dermira deal saw Lilly gain both a marketed drug – medicated cloth Qbrexza (glycopyrronium) for uncontrolled excessive underarm sweating – as well as pipeline candidate lebrikizumab for atopic dermatitis, which is currently
-
Lilly expands dermatology portfolio with $1.1bn Dermira deal
The pharma giant is also set to gain an additional phase 3 candidate from the deal – lebrikizumab, a monoclonal antibody designed to bind to IL-13 that is being evaluated for ... Roche had been developing lebrikizumab as a potential treatment for
-
Almirall eyes $62m takeover of multicytokine specialist Bioniz
The option deal comes amid an expansionist phase for Almirall, which exercised an option to buy Dermira’s anti-IL-13 antibody lebrikizumab – heading for phase 3 testing in atopic dermatitis
-
MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss
There are a number of drugs coming through the collective industry pipeline as well, including IL-13 inhibitors from Dermira (lebrikizumab) and Leo Pharma (tralokinumab) and oral JAK inhibitors such as
More from news
Approximately 4 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Pharma deals during August 2014
This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- A new era for UK-Japanese scientific research relations
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
